Association of interleukin 1 beta (IL-1β) polymorphism with mRNA expression and risk of non small cell lung cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Interleukin 1 beta (IL- 1β), a key proinflammatory cytokine encoded by the interleukin 1 beta gene, has been associated with chronic inflammation and plays an important role in lung inflammatory diseases including lung cancer. Elevated levels of Interleukin 1proteins, in particular interleukin 1 beta greatly enhance the intensity of the inflammatory response. AIM: To study the role of interleukin 1 beta-31C > T and -511 T > C polymorphism in the pathogenesis of non small cell lung cancer (NSCLC). MATERIALS AND METHODS: One hundred and ninety non small cell lung cancer patients and 200 healthy age, sex, smoking and dwelling matched controls were used for polymorphic analysis by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) followed by sequencing. Normal tissues of 48 histopathologically confirmed non small cell lung cancer patients were taken for mRNA expression analysis. Quantitation of interleukin 1 beta was carried out by quantitative real time PCR. RESULT: The T/T genotype of interleukin 1 beta-31 gene was significantly associated with increased risk of NSCLC [(P = 0.001, OR - 2.8 (95%CI 1.52-5.26)]. The interleukin 1 beta - 511 T > C does not show any difference between the NSCLC and control group (P = 0.3, OR - 0.72 (95%CI 0.41-1.28). Quantitative analysis of mRNA showed significant association with interleukin 1 beta T allele as compared to the interleukin 1 beta-31C allele (P = 0.006). CONCLUSION: We conclude that lung cancer risk genotype interleukin 1 beta-31TT results in increased expression of interleukin 1 beta mRNA in lung cancer patients. Our data suggest that this genotype (IL1β -31TT) in the interleukin 1 beta regulatory region provide a microenvironment with elevated inflammatory stimuli and thus increasing the risk for lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Avoidable global cancer deaths and total deaths from smoking
Jha, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2703 · Cited by 522
Inflammation and Lung Cancer: Roles of Reactive Oxygen/Nitrogen Species
Azad, N., Rojanasakul, Y., & Vallyathan, V. (2008) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400701436460 · Cited by 409 · cited 1×
“Interleukin 1 beta plays an important role in various inflammatory diseases including lung cancer (Azad et al., 2008; Mayne et al., 1999).”
Background
Cited by
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Mantovani, A., Dinarello, C. A., Molgora, M., & Garlanda, C. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.012 · Cited by 1,046
IL‐1 and IL‐1 regulatory pathways in cancer progression and therapy
Mantovani, A., Barajon, I., & Garlanda, C. (2018) · Immunological Reviews · doi:10.1111/imr.12614 · Cited by 376
Rébé, C., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12071791 · Cited by 337
Metadata
- Authors
- Bhat, I. A., Naykoo, N. A., Qasim, I., Ganie, F. A., Yousuf, Q., Bhat, B. A., Rasool, R., Aziz, S. A., & Shah, Z. A.
- Venue
- Meta Gene
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 2
- Pages
- 123-133
- ISSN
- 2214-5400 (ISSN-L)
- OpenAlex
- W2088244834
- Cited by
- 70
- References
- 2
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.